RFA-DA-23-002: Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users (R01- Clinical Trials Required)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on August 11, 2022.
From the official notice on Grants.gov, last changed April 6, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsRequired
- Funded byNIDA
- Median yearly award$1.1 million
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-DA-23-002 were run by National Institute on Drug Abuse (NIDA, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DA-23-002 in the NIH Guide.
Key dates
| Posted | April 6, 2022 |
|---|---|
| Deadline | August 11, 2022 |
| Archived by Grants.gov | September 16, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
oEnsuring all PLWH have rapid access to care, especially in resource-limited settings, remains a key challenge to the success of HIV care/treatment efforts. Same day or other rapid treatment initiation may be available, but patients may be concerned that other needs will make treatment difficult or they may face delays related to the enrollment process for treatment support mechanisms (e.g., ADAP, Ryan White, Medicaid). Similarly, long-term retention in HIV care and sustained achievement of viral suppression can be challenging even when ARV is introduced at or close to HIV diagnosis. Existing practices such as Strengths-Based Case Management and Patient Navigation often demonstrate a lack of efficacy among people with SUD. Persons with SUD and HIV often present clinical complexities and engagement with multiple services may be necessary; where reducing and eliminating barriers (i.e. structural or individual) to immediate linkage to care is critical to minimizing time between diagnosis and treatment and can lead to achieving Ending the Epidemic goals. Even with rapid ARV uptake, this population may need additional supports to remain continuously engaged in care. There is a need to develop and test evidence-based interventions at the systemic, organizational, and/or provider levels that can reduce the time between diagnosis and treatment while also retaining persons with SUD in HIV and SUD care.
Funded under RFA-DA-23-002 so far
NIH funded 1 project under RFA-DA-23-002 in fiscal 2023 to 2026, at 1 institution. The median yearly award was $1.1 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| PrEP and MOUD Rapid Access for Persons who Inject Drugs: the CHORUS+ Study | Boston Medical Center | 2026 | $1.1 million |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DA-23-002 still open?
No. It closed on August 11, 2022.
Who can apply for Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users (R01- Clinical Trials Required)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users (R01- Clinical Trials Required)?
Closed August 11, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-DA-23-002?
NIH RePORTER lists 1 project funded under RFA-DA-23-002 in fiscal 2023 to 2026, at 1 institution.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)